A novel isoxazole herbicide crystal form and its preparation method

By preparing a new crystal form I of isoxazole herbicides, the problems of stability and solubility were solved, and the processing efficiency and stability were improved. It is suitable for suspension formulations and can be applied in the field of agricultural herbicides.

CN123106653APending Publication Date: 2026-11-17JINGBO AGROCHEM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510632134.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The polymorphism of existing isoxazole herbicides affects their stability, storage, and transportation, leading to a reduction in the content of the active ingredient and impacting product quality and efficacy.

Method used

A novel isoxazole herbicide crystal form I was prepared by using specific methods of dissolution, addition of unsuitable solvents, and ultrasonic-induced crystallization to obtain crystal form I with characteristic XRD and DSC spectra, ensuring its low solubility in water, good processability, and suitability for suspension formulations.

Benefits of technology

Crystal form I has 80% lower solubility in water, improving processing efficiency. The suspending agent exhibits excellent stability under heat storage and low temperature conditions, conforms to green and environmentally friendly solvent systems, and is suitable for agricultural weed control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005407042430000061
    Figure BDA0005407042430000061
  • Figure BDA0005407042430000071
    Figure BDA0005407042430000071
  • Figure BDA0005407042430000081
    Figure BDA0005407042430000081
Patent Text Reader

Abstract

This invention provides crystalline form I of compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole, related products, preparation methods, and uses. Crystalline form I of this invention exhibits excellent solubility, good formulation processability, and high formulation stability. Furthermore, the preparation process of crystalline form I is simple, and the solvent system used is environmentally friendly and easy for industrial production. With these advantages, crystalline form I has great application potential in the field of agricultural weed control, not only bringing significant economic benefits to agricultural production but also aligning with the concept of green development, possessing broad market prospects and environmental benefits.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pesticide technology, specifically to a new crystal form of isoxazole herbicide and its preparation method. Background Technology

[0002] 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole belongs to the isoxazole class of herbicides. As a K3-type cell division inhibitor, its mechanism of action is to specifically inhibit VLCFA elongase, a key enzyme in fatty acid synthesis in plants, thereby blocking fatty acid biosynthesis and ultimately leading to plant death. This compound is absorbed through the young roots and shoots of weeds, effectively inhibiting early seedling growth and destroying meristems and coleoptiles. It can be widely used in pre-emergence soil treatment for various crops such as corn, wheat, and soybeans, exhibiting highly efficient and broad-spectrum herbicidal activity against annual grass weeds (such as foxtail, barnyard grass, and crabgrass) and annual broadleaf weeds (such as long-awned amaranth, millet grass, and purslane).

[0003] Polymorphism of a compound refers to the different arrangements of molecules in the solid state. Different polymorphs can significantly affect the physical and chemical properties of pesticides, thereby having a significant impact on their stability, storage, transportation, and processing. For example, polymorphs with poor stability are prone to degradation during storage and transportation, leading to a reduction in the content of active ingredients, which in turn affects product quality and efficacy.

[0004] Since its introduction, compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole has attracted much attention due to its excellent herbicidal effect and low dosage. However, developing new crystal forms of this compound is of significant practical importance and research value in order to further improve its efficacy, reduce environmental risks, and control production costs. Summary of the Invention

[0005] Purpose of the invention

[0006] In view of the needs or defects existing in the prior art, the purpose of this invention is to provide a new crystal form of compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole, its preparation method and uses.

[0007] Solution

[0008] To achieve the above objectives, the present invention adopts the following technical solution:

[0009] In a first aspect, the compound of the present invention, 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole, has crystal form I, wherein the X-ray powder diffraction pattern (XRD) of crystal form I obtained by Cu-Kα radiation has diffraction peaks at at least the following diffraction angles 2θ: 4.990°±0.2°, 9.950°±0.2°, 11.299°±0.2°, 13.820°±0.2°, 14.231°±0.2°, 14.580°±0.2°, 15.019°±0.2°, 17.690°±0.2°, 18.029°±0.2°, 18.278°±0.2°. °±0.2°, 19.460°±0.2°, 19.940°±0.2°, 20.340°±0.2°, 20.770°±0.2°, 21.600°±0.2°, 21.970°±0.2°, 22.471°±0.2°, 22.710°±0.2°, 24.330°±0.2°, 24. 991°±0.2°, 25.150°±0.2°, 25.379°±0.2°, 26.560°±0.2°, 26.920°±0.2°, 27.171°±0.2°, 29.710°±0.2°, 30.110°±0.2°, 30.281°±0.2°, 31.540°±0.2°.

[0010] In the specific implementation scheme, the XRD pattern of crystal form I obtained by Cu-Kα ray measurement is consistent with the accompanying drawings. Figure 1 The XRD patterns shown are basically the same.

[0011] The differential scanning calorimetry (DSC) curve of crystal form I at a heating rate of 10 °C / min shows characteristic endothermic peaks at 124 ± 3 °C and 132 ± 3 °C.

[0012] In a specific implementation, the DSC diagram of crystal form I at a heating rate of 10°C / min is shown in the attached figure of the specification. Figure 2 As shown.

[0013] In a specific implementation, the thermogravimetric analysis (TGA) diagram of crystal form I at a heating rate of 10 °C / min is shown in the attached figure of the specification. Figure 3 As shown; according to its TGA diagram, crystal form I is unsolvated and does not contain crystallization solvent.

[0014] In a second aspect, the present invention provides a method for preparing crystal form I as described in the first aspect above, the method comprising:

[0015] (1) The compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole and an organic solvent were added to a reaction vessel and stirred at 20°C to 60°C to dissolve the compound.

[0016] (2) Filter out the insoluble matter, collect the filtrate, and keep the collected filtrate at 20℃~60℃;

[0017] (3) Introduce ultrasound at a frequency of 10-20 kHz; at the same time, add water or alcohol to the reaction system as a poor solvent to induce crystallization. After the addition is complete, continue crystal growth under ultrasound conditions for 3-8 hours.

[0018] (4) Filter the reaction system, wash the filter cake with water, and then dry the filter cake at 50℃~80℃ to obtain the crystal form I.

[0019] Preferably, in step (1), the organic solvent is selected from any one or more of the following: dimethylformamide, dimethylacetamide, dimethyl sulfoxide and / or N-methylpyrrolidone.

[0020] Preferably, in step (1), the mass-to-volume ratio of the compound to the organic solvent, expressed in mg / mL, is 1:(5-20), for example, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20 or any value between them.

[0021] Preferably, in step (3), the rate at which the undesirable solvent is added is 0.2 ml / min to 0.5 ml / min;

[0022] Preferably, in step (3), the volume ratio of the undesirable solvent added to the organic solvent added in step (1) is 0.5 to 2:1.

[0023] Preferably, in step (3), the alcohol is selected from any one or more of the following: methanol, ethanol and / or isopropanol.

[0024] Thirdly, the present invention provides a pesticide composition comprising crystal form I as described in the first aspect above.

[0025] Fourthly, the present invention provides a pesticide formulation comprising: crystal form I as described in the first aspect above or a pesticide composition as described in the third aspect above, and at least one pesticide-acceptable excipient.

[0026] Fifthly, the present invention provides the use of the crystal form I as described in the first aspect above, the pesticide composition as described in the third aspect above, or the pesticide formulation as described in the fourth aspect above as a herbicide for selective control of weeds in crops.

[0027] In a sixth aspect, the present invention provides a method for controlling weeds in crops, the method comprising: applying an effective amount of crystal form I as described in the first aspect above, a pesticide composition as described in the third aspect above, or a pesticide formulation as described in the fourth aspect above to the crop, its growing area, and / or seeds.

[0028] Beneficial effects

[0029] This invention provides crystal form I of compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole, related products, preparation methods, and uses. Compared to the prior art crystal form of this compound, crystal form I of this invention has the following significant advantages:

[0030] 1) It has low solubility in water, which is more conducive to the preparation of aqueous suspensions. Specifically, compared with the prior art crystal form A, the solubility of crystal form I in water of the present invention is reduced by nearly 80%. This significant decrease in solubility allows crystal form I to be dispersed more stably in the aqueous suspension system, and it is less likely to cause crystal growth or precipitation.

[0031] 2) Better formulation processability. When processed into a suspension dosage form, under the same grinding conditions, the grinding efficiency of crystal form I of the present invention is significantly higher than that of the crystal form in the prior art, thereby greatly shortening the processing cycle, reducing energy consumption, and effectively improving production efficiency.

[0032] 3) High formulation stability. In the thermal storage and low temperature stability tests of the suspension formulation, crystal form I performed excellently; specifically, after a specified period of thermal storage or refrigeration, the suspension rate of the suspension prepared from crystal form I remained stable, the particle size did not change significantly, and no sediment was formed. This fully demonstrates its good stability under different environmental conditions, ensuring the reliable quality of the product during storage and transportation.

[0033] Furthermore, the crystal form I preparation process of this invention is simple, the solvent system used is green and environmentally friendly, conforms to the concept of sustainable development, and has strong feasibility for industrial application.

[0034] In view of the above, the crystalline form I of 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole provided by the present invention shows great application potential and broad market prospects in the field of agricultural weed control, and is expected to bring significant economic and environmental benefits to agricultural production. Attached Figure Description

[0035] One or more embodiments are illustrated by way of example with reference to the accompanying drawings, and these illustrative examples are not intended to limit the embodiments. The term "illustrative" as used herein means "serving as an example, embodiment, or illustration." Any embodiment illustrated herein as "illustrative" is not necessarily to be construed as superior to or better than other embodiments.

[0036] Figure 1 The image shows the X-ray powder diffraction (XRD) pattern of crystal form I prepared in Example 1.

[0037] Figure 2 The image shows the differential scanning calorimetry (DSC) curve of crystal form I prepared in Example 1.

[0038] Figure 3 The thermogravimetric (TGA) diagram is shown for crystal form I prepared in Example 1.

[0039] Figure 4 The XRD pattern of crystal form A prepared in Example 1 under the same detection conditions. Detailed Implementation

[0040] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions of this invention will be clearly and completely described below in conjunction with embodiments. Obviously, the described embodiments are only some, not all, of the embodiments of this invention. All other embodiments obtained by those skilled in the art based on the embodiments of this invention without creative effort are within the scope of protection of this invention.

[0041] Furthermore, to better illustrate the present invention, numerous specific details are provided in the following detailed embodiments. Those skilled in the art should understand that the present invention can be practiced without certain specific details. In some embodiments, materials, elements, methods, and means well known to those skilled in the art are not described in detail in order to highlight the spirit of the invention.

[0042] Unless otherwise expressly stated, throughout the specification and claims, the term "comprising" or its variations such as "including" or "comprises" shall be understood to include the stated elements or components without excluding other elements or other components.

[0043] The present invention will be further described in detail below through examples.

[0044] Unless otherwise specified, the reagents and other materials used in the following examples are commercially available.

[0045] Example 1

[0046] 10g of compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole and 50ml of dimethylformamide were added to a reaction vessel and stirred at 60℃ for 30min until equilibrium was reached. The insoluble matter was filtered off, and the filtrate was collected and maintained at 60℃. Ultrasonic induction crystallization was introduced at a frequency of 10kHz, while 100ml of purified water was added dropwise at a rate of 0.2ml / min. After the addition was complete, crystallization was continued for 3h. The mixture was filtered, washed with a small amount of purified water, and the filter cake was vacuum dried at 50℃ to constant weight to obtain 9.4g of white powder product.

[0047] The obtained product was subjected to X-ray powder diffraction (XRD) analysis under the following conditions: Rigaku (Miniflex 600 type), copper target, tube voltage 40 kV, tube current 15 mA, scanning angle range 3°–50°, scanning speed 20° / min, scanning step size 0.01°; its XRD pattern is shown below. Figure 1 As shown. By Figure 1 Therefore, the crystal form I obtained by the above procedure is the crystal form of the present invention.

[0048] Furthermore, the obtained product was subjected to differential scanning calorimetry (DSC) analysis under the following conditions: A TA (DSC25 type) instrument was used, with indium as the temperature / thermal calibrator, under nitrogen protection, with a heating rate of 10℃ / min and a temperature range of 40–150℃ (313.15–423.15K); the DSC chromatogram is shown below. Figure 2 As shown.

[0049] In addition, the obtained product was subjected to thermogravimetric analysis (TGA) under the following conditions: TA (TGA55 type) instrument, using nickel as the temperature calibrator, under nitrogen atmosphere, with a heating rate of 10℃ / min, and a temperature range of 20–290℃ (293.15–563.15K); its DSC chromatogram is shown below. Figure 3 As shown.

[0050] Example 2

[0051] 10g of compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole and 100ml of dimethyl sulfoxide were added to a reaction vessel and stirred at 40℃ for 30min until equilibrium was reached. The insoluble matter was filtered off, and the filtrate was collected and maintained at 40℃. Ultrasonic induction crystallization was introduced at a frequency of 15kHz, while 120ml of purified water was added dropwise at a rate of 0.3ml / min. After the addition was complete, crystallization was continued for 5h. The mixture was filtered, washed with a small amount of purified water, and the filter cake was vacuum dried at 50℃ to constant weight to obtain 9.3g of white powder product.

[0052] Using the same XRD detection conditions as in Example 1, the obtained product was subjected to XRD pattern detection, confirming that it is crystal form I of the present invention.

[0053] Example 3

[0054] 10g of compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole and 80ml of dimethylacetamide were added to a reaction vessel and stirred at 50℃ for 30min until equilibrium was reached. The insoluble matter was filtered off, and the filtrate was collected and maintained at 50℃. Ultrasonic induction crystallization was introduced at a frequency of 15kHz, while 120ml of purified water was added dropwise at a rate of 0.5ml / min. Crystallization continued for 4h after the addition was complete. The mixture was filtered, washed with a small amount of purified water, and the filter cake was vacuum dried at 50℃ to constant weight to obtain 9.4g of white powder product.

[0055] Using the same XRD detection conditions as in Example 1, the obtained product was subjected to XRD pattern detection, confirming that it is crystal form I of the present invention.

[0056] Example 4

[0057] 10g of compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole and 200ml of N-methylpyrrolidone were added to a reaction vessel and stirred at 20°C for 30min until equilibrium was reached. The insoluble matter was filtered off, and the filtrate was collected and maintained at 20°C. Ultrasonic induction crystallization was introduced at a frequency of 20kHz, while 100ml of anhydrous ethanol was added dropwise at a rate of 0.4ml / min. After the addition was complete, crystallization continued for 8h. The mixture was filtered, washed with a small amount of purified water, and the filter cake was vacuum dried at 50°C to constant weight to obtain 9.0g of white powder product.

[0058] Using the same XRD detection conditions as in Example 1, the obtained product was subjected to XRD pattern detection, confirming that it is crystal form I of the present invention.

[0059] Example 5

[0060] 10g of compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole and 150ml of dimethylformamide were added to a reaction vessel and stirred at 30℃ for 30min until equilibrium was reached. The insoluble matter was filtered off, and the filtrate was collected and maintained at 30℃. Ultrasonic induction crystallization was introduced at a frequency of 20kHz, while 250ml of methanol was added dropwise at a rate of 0.2ml / min. After the addition was complete, crystallization continued for 5h. The mixture was filtered, washed with a small amount of purified water, and the filter cake was vacuum dried at 50℃ to constant weight to obtain 9.4g of white powder product.

[0061] Using the same XRD detection conditions as in Example 1, the obtained product was subjected to XRD pattern detection, confirming that it is crystal form I of the present invention.

[0062] Example 6

[0063] 10g of compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole and 140ml of dimethyl sulfoxide were added to a reaction vessel and stirred at 400℃ for 30min until equilibrium was reached. The insoluble matter was filtered off, and the filtrate was collected and maintained at 40℃. Ultrasonic induction crystallization was introduced at a frequency of 10kHz, while 140ml of isopropanol was added dropwise at a rate of 0.5ml / min. After the addition was complete, crystallization continued for 6h. The mixture was filtered, washed with a small amount of purified water, and the filter cake was vacuum dried at 50℃ to constant weight to obtain 9.2g of white powder product.

[0064] Using the same XRD detection conditions as in Example 1, the obtained product was subjected to XRD pattern detection, confirming that it is crystal form I of the present invention.

[0065] Experimental Example 1: Preparation of Crystal Form A

[0066] Following the method provided in patent CN112969697, crystalline form A of compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole was prepared. The obtained product was subjected to XRD analysis under the same XRD conditions as in Example 1, and the XRD pattern is shown below. Figure 4 As shown.

[0067] Experimental Example 2: Solubility Study

[0068] In this experimental example, the solubility of crystal form I prepared in Examples 1-6 and crystal form A prepared in Experiment 1 were compared.

[0069] Specifically, the solubility of the crystal products obtained in Examples 1 to 6 in water was tested, and the crystal form A obtained in Example 1 was tested six times. The results are shown in Table 1 below.

[0070] Table 1

[0071]

[0072] To investigate the difference in solubility between crystal form A and crystal form I of this invention in water, independent samples t-tests were performed on the two sets of solubility data using SPSS 27.0. The results are shown in Table 2 below.

[0073] Table 2

[0074]

[0075] As shown in Table 2, the mean solubility of group 1 was 3.100±0.155 mg / L, and the mean solubility of group 2 was 5.533±0.151 mg / L. This indicates that the solubility of crystal form I in water is reduced by nearly 80% compared with that of crystal form A in the prior art. An independent samples t-test was performed on the solubility of the two groups, and the result was t=27.591, p<0.001, which shows that the difference in solubility between the two groups is statistically significant.

[0076] As is well known, when preparing aqueous suspensions of crystalline forms, the lower the solubility of the crystalline form in water, the more stably it can be dispersed in the aqueous suspension, which is more conducive to obtaining an aqueous suspension system with excellent performance. From the above results, it can be concluded that when preparing suspensions, the solubility performance of crystalline form I of the present invention in water has a significant advantage over that of crystalline form A in the prior art.

[0077] Experimental Example 3: Formulation Processability Study

[0078] In this experimental example, the crystal form I prepared in Example 1 and the crystal form A prepared in Experimental Example 1 were subjected to a formulation processability study.

[0079] Specifically, the following methods are used to process crystal form I and crystal form A into suspension formulations respectively:

[0080] The mixture consists of 40% technical grade compound, 3% phosphate ester dispersant, 2% carboxylate dispersant, 1% isomeric alcohol ether wetting agent, 5% ethylene glycol, 0.3% organosilicon defoamer, 0.5% magnesium aluminum silicate, and deionized water to a final volume of 100%. All materials are weighed and mixed thoroughly according to the above proportions, then poured into a 200ml grinding jar for grinding. The material and zirconium beads are added at a weight ratio of 1:1, along with 95% zirconium oxide beads with a diameter range of 0.8-1.0mm. The grinding speed is set to 2000rpm. After grinding for 60 minutes, the mixture is sieved through an 80-mesh sieve to obtain the suspension sample.

[0081] To further explore the difference in grinding efficiency between the two crystalline drug formulations, the following records were made:

[0082] i) Under the same grinding conditions and for the same grinding time, the crystal particle size (D10 / D50 / D90) and its suspension rate (%), and

[0083] ii) The grinding time required to grind to the same particle size (D90) under the same grinding conditions.

[0084] The particle size of the crystals in the obtained suspension samples was detected by a laser particle size analyzer, and the suspension rate of the formulation was detected by the GB / T 14825 method for determining the suspension rate of pesticides.

[0085] The results are as follows:

[0086] i) Under the same grinding conditions, the particle size distribution and suspension rate of the crystals obtained by grinding for the same time are shown in Table 3 below.

[0087] Table 3

[0088]

[0089] ii) Under the same grinding conditions, the grinding time required to grind to the same particle size (same D90) is shown in Table 4 below.

[0090] Table 4

[0091]

[0092] Under the same grinding conditions and for the same grinding time, the smaller the particle size of the suspending agent, the higher the grinding efficiency; at the same time, the higher the suspension rate, the more stable the suspension performance of the suspension system.

[0093] Alternatively, under the same grinding conditions, the less grinding time required to grind to the same particle size, the higher the grinding efficiency.

[0094] Table 3 above shows that, compared with the prior art crystal form A, under the same grinding conditions and with the same grinding time, the suspending agent prepared by crystal form I of the present invention has a smaller particle size and a higher suspension rate, thus having more stable suspension performance; it also shows that crystal form I of the present invention has a higher grinding efficiency than crystal form A of the prior art when preparing suspending agent dosage forms.

[0095] Table 4 above shows that, compared with the prior art crystal form A, under the same grinding conditions, the crystal form I of the present invention requires less grinding time to grind to the same particle size (D90 is about 5.0 μm); this further illustrates that the crystal form I of the present invention has higher grinding efficiency than the prior art crystal form A.

[0096] The results above show that, when preparing suspension formulations, crystal form I of the present invention has a higher grinding efficiency than crystal form A of the prior art.

[0097] Example 4: Formulation Stability Test

[0098] In this experimental example, the suspensions of crystal form I and crystal form A prepared under the same grinding conditions and ground to the same particle size (D90 of about 5.0 μm) in Experiment 3 were subjected to thermal storage stability and low temperature stability tests to compare the stability of the formulations of the two crystal forms.

[0099] Specifically, according to GB / T 19136-2021 Method for Determination of Thermal Stability of Pesticides and GB / T 19137-2003 Method for Determination of Low Temperature Stability of Pesticides, the two crystalline suspension samples (two copies each) prepared in Example 3 were placed at 54℃±2℃ and 0℃±2℃ for 14 days, respectively. After 14 days, each suspension sample was taken out and allowed to stand for 2 hours to return to room temperature. Then the content, suspension rate and particle size of the crystalline form were detected. The results are shown in Table 5 below.

[0100] Table 5

[0101]

[0102] Furthermore, the dispersion stability of the suspension samples after the above thermal storage and low-temperature experiments was tested. Specifically, 100ml stoppered graduated cylinders and standard hard water were used to dilute the suspension 20 times, and then the samples were allowed to stand for 0.5h, 2h, and 24h, respectively, and the presence or amount of sediment (expressed in ml volume) was observed. The results are shown in Table 6 below.

[0103] Table 6

[0104]

[0105] As can be seen from Tables 5 and 6:

[0106] (1) The suspension sample prepared by crystal form I of the present invention showed a 0.4% decrease in suspension rate and a 5.8% increase in particle size after 14 days of heat storage, and a 0.1% decrease in suspension rate and no increase in particle size after 14 days of low-temperature storage; while the suspension sample prepared by crystal form A of Experimental Example 1 showed a 3.7% decrease in suspension rate and a 70.6% increase in particle size after 14 days of heat storage, and a 0.8% decrease in suspension rate and a 7.8% increase in particle size after 14 days of low-temperature storage.

[0107] (2) The suspension sample prepared by crystal form I of the present invention did not show any sediment after 14 days of hot storage or low temperature storage, indicating that it still has good dispersion stability after hot storage or low temperature storage; while the suspension sample prepared by crystal form A of Experimental Example 1 showed obvious sediment after 14 days of hot storage, indicating that its dispersion stability decreased significantly after hot storage.

[0108] The above results show that the suspension sample prepared by crystal form I of the present invention exhibits better cold and hot storage stability, thus better exerting the efficacy and meeting the spraying needs of aerial spraying, etc. In contrast, the suspension sample prepared by crystal form A of Experimental Example 1 has significantly lower hot storage stability. Therefore, crystal form I of the present invention exhibits superior stability after being processed into a suspension formulation compared to the crystal forms of the prior art.

[0109] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A crystalline Form I of the compound 3-(((5-(difluoromethoxy)-l-methyl-3- (trifluoromethyl)-lH-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole, characterized by, The X-ray powder diffraction pattern of crystal form I obtained using Cu-Kα rays shows diffraction peaks at at least the following diffraction angles 2θ: 4.990°±0.2°, 9.950°±0.2°, 11.299°±0.2°, 13.820°±0.2°, 14.231°±0.2°, 14.580°±0.2°, 15.019°±0.2°, 17.690°±0.2°, 18.029°±0.2°, 18.278°±0.2°, 19.460°±0.2°, 19.940°±0.2°, and 20.340°±0.2°. 2°, 20.770°±0.2°, 21.600°±0.2°, 21.970°±0.2°, 22.471°±0.2°, 22.710°±0.2°, 24.330°±0.2°, 24.991°±0.2°, 25.150°±0.2°, 25.379°±0.2°, 26.560°±0.2°, 26.920°±0.2°, 27.171°±0.2°, 29.710°±0.2°, 30.110°±0.2°, 30.281°±0.2°, 31.540°±0.2°.

2. The crystalline Form I of claim 1, characterized by, The X-ray powder diffraction pattern of crystal form I obtained by measuring with Cu-Kα rays is basically the same as the X-ray powder diffraction pattern shown in Figure 1 of the specification.

3. The crystalline Form I of claim 1 or 2, characterized by, In the differential scanning calorimetry (DSC) plot of crystal form I at a heating rate of 10 °C / min, characteristic endothermic peaks are observed at 124 ± 3 °C and 132 ± 3 °C.

4. The crystalline Form I of claim 3, characterized by, The differential scanning calorimetry (DSC) curve of crystal form I at a heating rate of 10 °C / min is shown in Figure 2 of the specification.

5. The crystalline Form I of claim 1 or 2, characterized by, Crystal form I is unsolvated and does not contain crystallization solvent.

6. A process for preparing the crystalline Form I according to any one of claims 1 to 5, characterized in that, The preparation method includes: (1) The compound 3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)sulfonyl)-5,5-dimethyl-4,5-dihydroisoxazole and an organic solvent were added to a reaction vessel and stirred at 20°C to 60°C to dissolve the compound. (2) Filter out the insoluble matter, collect the filtrate, and keep the collected filtrate at 20℃~60℃; (3) Introduce ultrasound at a frequency of 10-20 kHz; at the same time, add water or alcohol to the reaction system as a poor solvent to induce crystallization. After the addition is complete, continue crystal growth under ultrasound conditions for 3-8 hours. (4) Filter the reaction system, wash the filter cake with water, and then dry the filter cake at 50℃~80℃ to obtain the crystal form I.

7. The production method according to claim 6, wherein In step (1), the organic solvent is selected from any one or more of the following: dimethylformamide, dimethylacetamide, dimethyl sulfoxide and / or N-methylpyrrolidone; And / or, the mass-to-volume ratio of the compound to the organic solvent, in g / mL, is 1:(5-20).

8. The preparation method according to claim 6, characterized in that, In step (3), the rate at which the unsuitable solvent is added is 0.2 ml / min to 0.5 ml / min; And / or, the volume ratio of the unsuitable solvent added to the organic solvent added in step (1) is 0.5 to 2:1; And / or, the alcohol is selected from any one or more of the following: methanol, ethanol and / or isopropanol.

9. A pesticide composition comprising crystal form I according to any one of claims 1-5.

10. A pesticidal formulation comprising: The crystal form I according to any one of claims 1-5 or the pesticide composition according to claim 9, and at least one pesticide-acceptable excipient.

11. The use of the crystal form I according to any one of claims 1-5, the pesticide composition according to claim 9, or the pesticide formulation according to claim 10 as a herbicide for selective control of weeds in crops.

12. A method of controlling weeds in crops, characterized by, The method comprises applying an effective amount of crystal form I according to any one of claims 1-5, the pesticide composition according to claim 9, or the pesticide formulation according to claim 10 to the crop, its growing site, and / or seeds.